Tianda Pharmaceuticals Ltd. (0455) AI Stock Analysis

• Market Cap: HK$215.00M
• Dividend Yield: N/A
• Average Volume (3M): 84.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.37
• Revenue Growth: -19.28%
• EPS Growth: -42.27%
• Country: HK
• Employees: 701
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.02
• Shares Outstanding: 2,150,041,700
• 10 Day Avg. Volume: 115,400
• 30 Day Avg. Volume: 84,945
• PEG Ratio: -0.04
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 1.10
• P/FCF Ratio: -6.95
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: HK$0.10 ▼(-24.62% Downside)
• Action: Reiterated Date: 01/08/26
• Date: Action: Reiterated 01/08/26

The score is primarily held down by weak financial performance, including declining revenue, ongoing losses, and negative operating cash flow. Technical indicators are mixed with only modest near-term improvement against a longer-term downtrend, while valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.

Positive Factors

Diversified revenue streams

Tianda's revenue model spans prescription drugs, OTC products and traditional Chinese medicine plus licensing and distribution partnerships. This diversification reduces dependence on a single product or channel, supporting steadier demand and resilience across healthcare segments over months.

Manageable leverage

A moderate debt-to-equity ratio (0.25) indicates limited financial leverage, lowering interest burden and preserving capacity to fund R&D or working capital. This balance sheet conservatism supports financial flexibility and reduces refinancing risk over a multi-month horizon.

Improving free cash flow growth

Reported improvement in free cash flow growth signals that management may be extracting more cash from operations or capital efficiency gains. If sustained, better free cash flow improves liquidity and reduces reliance on external funding for investment or debt service.

Negative Factors

Declining revenue

A sharp revenue decline (-14.23%) erodes scale and bargaining power, squeezing gross margins and reducing funds available for R&D, marketing and commercialization. Continued top-line contraction would undermine long-term competitiveness and investment capacity.

Ongoing losses and negative operating cash flow

Sustained net losses and negative operating cash flow deplete equity and constrain operational flexibility. Over time this can force asset sales, dilution, or increased borrowing, limiting the company's ability to invest in drug development or expand commercial efforts.

Negative return on equity

A negative ROE indicates the company is destroying shareholder capital, reflecting unprofitable operations and weak margins. Persisting negative ROE reduces investor confidence and hampers the firm's ability to attract equity financing for long-term growth initiatives.

Tianda Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. Its product range includes Chinese medicines, chemical drugs, biological and health products, and medical appliances covering the area of cardio-cerebrovascular, pediatric, anti-flu and respiratory, anti-infection, detoxification, urological agents, and others. The company offers its health products under the Herb Valley and Tuokang brands. It also engages in the sale and wholesale of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicines; provision of Chinese medical services; and trading of agricultural by-products. The company was formerly known as Tianda Holdings Limited and changed its name to Tianda Pharmaceuticals Limited in September 2012. The company was incorporated in 1992 and is headquartered in Central, Hong Kong. Tianda Pharmaceuticals Limited is a subsidiary of Tianda Group Limited.

How the Company Makes Money

Tianda Pharmaceuticals generates revenue through multiple streams, including the sale of prescription medications, OTC products, and traditional Chinese medicine. The company's revenue model is based on direct sales to healthcare providers, pharmacies, and hospitals, as well as distribution agreements with third-party partners. Key revenue streams include the licensing of its proprietary products and formulations, which allows the company to expand its market reach. Additionally, Tianda may benefit from collaborations with research institutions or other pharmaceutical companies that enhance its product development capabilities and market presence. Factors contributing to its earnings also include market demand for its diversified product portfolio and strategic marketing initiatives aimed at increasing brand awareness.

Tianda Pharmaceuticals Ltd. Financial Statement Overview

Summary

Weak fundamentals driven by a sharp revenue decline (-14.23%) and persistent losses (negative net profit and EBIT margins). Balance sheet leverage is moderate (debt-to-equity 0.25), but negative ROE and negative operating cash flow signal continued financial strain.

Income Statement

Tianda Pharmaceuticals Ltd. has experienced a significant decline in revenue, with a negative growth rate of -14.23% in the latest year. The company is struggling with profitability, as indicated by negative net profit and EBIT margins. The gross profit margin remains relatively stable, but the overall financial performance is weak due to consistent losses.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.25, indicating a manageable level of leverage. However, the return on equity is negative, reflecting ongoing losses and poor returns for shareholders. The equity ratio is stable, suggesting a solid asset base, but the lack of profitability is a concern.

Cash Flow

Tianda Pharmaceuticals Ltd. has shown some improvement in free cash flow growth, but the operating cash flow remains negative. The company struggles to generate cash from operations, and the free cash flow to net income ratio is zero, indicating inefficiencies in converting profits into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	384.68M	329.94M	532.09M	546.69M	509.96M	474.33M
Gross Profit	176.28M	152.02M	255.53M	251.52M	241.22M	258.99M
EBITDA	-9.97M	-49.49M	15.66M	-19.89M	-5.14M	-6.25M
Net Income	-47.26M	-61.37M	-24.16M	-54.64M	-21.67M	-25.92M
Balance Sheet
Total Assets	804.77M	765.02M	917.29M	1.09B	1.16B	1.13B
Cash, Cash Equivalents and Short-Term Investments	103.77M	85.69M	162.44M	343.44M	334.00M	234.98M
Total Debt	98.81M	127.44M	113.60M	141.05M	160.43M	145.53M
Total Liabilities	260.34M	259.36M	325.35M	434.23M	375.08M	342.97M
Stockholders Equity	544.55M	505.84M	592.07M	627.83M	756.75M	756.71M
Cash Flow
Free Cash Flow	-43.08M	-52.30M	-116.04M	54.73M	-61.98M	-184.08M
Operating Cash Flow	-26.10M	-9.70M	-49.76M	79.11M	-8.23M	-37.63M
Investing Cash Flow	-42.53M	-31.77M	-69.10M	-12.20M	86.35M	-137.73M
Financing Cash Flow	-59.61M	-30.65M	-57.39M	-28.98M	-1.29M	90.75M

Tianda Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0455, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.11, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 34.15 is Neutral, neither overbought nor oversold. The STOCH value of 6.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0455.

Tianda Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8329	54 Neutral	HK$246.67M	7.11	0.75%	3.51%	-5.98%	-81.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1652	49 Neutral	HK$801.39M	-2.84	-48.86%	―	-43.46%	-96.48%
1011	48 Neutral	HK$492.20M	-3.17	20.98%	―	―	―
8622	48 Neutral	HK$182.99M	-38.07	-8.71%	―	2.54%	33.33%
0897	46 Neutral	HK$376.91M	43.63	-1.16%	7.50%	59.60%	-351.02%
0455	44 Neutral	HK$215.00M	-3.19	-11.18%	―	-19.28%	-42.27%